Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor

• References

• 1 Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AHJT, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briet E. Mortality and causes of death in Dutch haemophiliacs. Br J Haematol 1989; 71: 71-6.
• 2 Small M, Jack AS, Lowe GDO, Mutch AF, Forbes CD, Prentice CRM. Coronary artery disease in severe haemophilia. Br Heart J 1983; 49: 604-7.
• 3 Lickfett L, Hagendorff A, Jung W, Pizzulli L, Brackmann HH, Luderitz B. Akuter Hinterwandinfarkt nach Faktor-VIII-Konzentrat bei schwerer Hamophilie A. Dtsch med Wschr 1998; 123: 658-62.
• 4 Kopitsky RG, Geltman EM. Unstable angina associated with factor VIII concentrate therapy for hemophilia A. Ann Intern Med 1986; 105: 215-6.
• 5 Lusher J. Use of prothrombin complex concentrates in the management of bleeding in hemophiliacs with inhibitors-Benefits and limitations. Seminars in Hematology 1994; 31: 49-52.
• 6 Sullivan DW, Purdy LJ, Billingham M, Glader BE. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics 1984; 74: 279-81.
• 7 Karayalcin G, Goldberg B, Cherrick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor. Am J Pediatr Hematol Oncol 1993; 15: 416-9.
• 8 Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64: 309-11.
• 9 Chavin SI, Siegel DM, Rocco TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and factor VIII inhibitor. Am J Med 1988; 85: 245-9.
• 10 Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, Mc Pherson J, Preston E, Scheibel E, Shulman M. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 01) 118-23.
• 11 Roberts HR. Clinical experience with activated recombinant factor VII: focus on safety aspects. Blood Coag Fibrinol 1998; 9 (Suppl. 01) 119-20.
• 12 Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-71.
• 13 Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
• 14 Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost 1999; 81: 245-9.
• 15 Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coag Fibrinol 1998; 9 (Suppl. 01) 147-52.